Cullinan Therapeutics, Inc. (CGEM) Revenue Growth
Cullinan Therapeutics, Inc. (CGEM) year-over-year revenue growth rate history. Analyze revenue growth in Excel with MarketXLS.
Revenue Growth Data
| Period | YoY Revenue Growth |
|---|---|
| 2022-12-31 | -99.47% |
| 2023-12-31 | 400.00% |
| 2024-12-31 | N/A |
| 2025-12-31 | N/A |
How CGEM compares with sector peers
| Symbol | Company | Revenue growth (latest fiscal year) |
|---|---|---|
| INMB | INmune Bio Inc. | 257.14% |
| ALT | Altimmune Inc. | 105.00% |
| NVAX | Novavax Inc. | 64.69% |
| LXRX | Lexicon Pharmaceuticals Inc. | 60.24% |
| RFL | Rafael Holdings Inc. Class B | 43.96% |
These are five companies in the same sector as CGEM with a comparable annual revenue growth. Each figure above is that company's most recent completed fiscal year, read from the same annual statements as the table on its own page, so the period end dates can differ between rows.
Get Cullinan Therapeutics, Inc. Data in Excel
Stream real-time stock prices and financials directly into your spreadsheets with MarketXLS.
Try: =hf_Revenue_Growth("CGEM", 2024)
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Volume |
| 2 | CGEM | $22.09 | -0.32% | 0.56M |
| 3 | ||||
| 4 | ||||
| 5 |